We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

41 hedge funds and large institutions have $254M invested in UroGen Pharma in 2017 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 4

76% more capital invested

Capital invested by funds: $145M → $254M (+$110M)

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

32% more funds holding

Funds holding: 31 → 41 (+10)

16.73% more ownership

Funds ownership: 35.14% → 51.88% (+17%)

Holders
41
Holders Change
+10
Holders Change %
+32.26%
% of All Funds
0.93%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
14
Increased
13
Reduced
8
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MMH
Menora Mivtachim Holdings
Israel
+$33.5M
2
CCM
Consonance Capital Management
New York
+$32.6M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$8.18M
4
CS
Credit Suisse
Switzerland
+$4.42M
5
Renaissance Technologies
Renaissance Technologies
New York
+$3.76M

Top Sellers

Rank Fund Capital Flow
1
PAI
ProQuest Associates IV
Florida
-$12.6M
2
Jennison Associates
Jennison Associates
New York
-$4.68M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.83M
4
PA
Perceptive Advisors
New York
-$2.49M
5
BII
Bainco International Investors
Massachusetts
-$2.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
26
ARK Investment Management
Florida
$345K +$331K +9,284 New
Two Sigma Investments
27
Two Sigma Investments
New York
$277K +$265K +7,436 New
Geode Capital Management
28
Geode Capital Management
Massachusetts
$265K – – –
EMG
29
ETF Managers Group
New Jersey
$264K +$244K +6,845 New
Goldman Sachs
30
Goldman Sachs
New York
$234K +$224K +6,300 New
MA
31
MYDA Advisors
New York
$223K +$214K +6,000 New
JP Morgan Chase
32
JP Morgan Chase
New York
$185K -$7.51K -211 -4%
CI
33
Clal Insurance
Israel
$166K +$159K +4,461 New
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$140K +$71.4K +2,005 +115%
VanEck Associates
35
VanEck Associates
New York
$105K +$101K +2,824 New
UBS Group
36
UBS Group
Switzerland
$102K +$62.2K +1,746 +175%
Norges Bank
37
Norges Bank
Norway
$50K – – –
AAMU
38
Amundi Asset Management US
Massachusetts
$41K +$39.2K +1,100 New
PA
39
Parallel Advisors
California
$30K – – –
CCA
40
Catalyst Capital Advisors
New York
$14K – – –
Macquarie Group
41
Macquarie Group
Australia
$11K +$10.7K +300 New
Jennison Associates
42
Jennison Associates
New York
– -$4.68M -148,575 Closed
BII
43
Bainco International Investors
Massachusetts
– -$2.28M -72,461 Closed
State of Tennessee, Department of Treasury
44
State of Tennessee, Department of Treasury
Tennessee
– -$158K -5,010 Closed
TRCT
45
Tower Research Capital (TRC)
New York
– -$10K -318 Closed
1
2

URGN Hedge Fund Activity: Q4 2017 in Review

41 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q4 2017, worth a combined $254M — up 76% from $145M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new URGN positions and 4 closed out — a net gain of 10 holders — while 13 added to existing stakes and 8 trimmed.

The largest buyer was Menora Mivtachim Holdings, adding an estimated $33.5M. The largest seller was ProQuest Associates IV, cutting an estimated $12.6M.

  • 41 institutional investors held UroGen Pharma (URGN) as of Q4 2017, up from 31 in Q3 2017.
  • Funds reported $254M of UroGen Pharma stock for Q4 2017, up 76% quarter-over-quarter.
  • 14 funds opened new UroGen Pharma positions in Q4 2017 and 4 closed out, a net change of +10 holders.
  • The largest UroGen Pharma buyer in Q4 2017 was Menora Mivtachim Holdings, an estimated $33.5M added.
  • The largest UroGen Pharma seller in Q4 2017 was ProQuest Associates IV, an estimated $12.6M sold.

Based on aggregated 13F filings for Q4 2017.